RankingsPricing
  1. US-listed companies
  2. Ultragenyx Pharmaceutical Inc.
  3. Financials
  4. Retained earnings

Ultragenyx Pharmaceutical Inc.RARE

Market cap
$3.2B
P/E ratio
SummaryFinancials
Period EndRetained earnings (Million USD)YoY (%)
Dec 31, 2024-3,957+16.80%
Dec 31, 2023-3,388+21.81%
Dec 31, 2022-2,781+34.12%
Dec 31, 2021-2,074+28.03%
Dec 31, 2020-1,620+13.02%
Dec 31, 2019-1,433+39.09%
Dec 31, 2018-1,030+23.73%
Dec 31, 2017-833+56.95%
Dec 31, 2016-531+86.37%
Dec 31, 2015-285+104.73%
Dec 31, 2014-139

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)